Mersana Therapeutics Announces Upcoming Presentations at 2023 ASCO Annual Meeting

Rhea-AI Summary

Mersana Therapeutics, a clinical-stage biopharmaceutical company focused on antibody-drug conjugates, has announced multiple abstracts accepted for presentation at the 2023 ASCO Annual Meeting in Chicago from June 2-6, 2023.

The key presentations include:

• XMT-1660: A phase 1b trial targeting breast and ovarian cancers (Abstract Number: TPS3154), presented by Erika Hamilton, MD on June 3.
• Correlating NaPi2b and FRa: Study on ovarian cancer (Abstract Number: 5545), presented by Debra Richardson, MD on June 5.
• UP-NEXT: A study of upifitamab rilsodotin in recurrent ovarian cancer (Abstract Number: TPS5614), also by Debra Richardson, MD on June 5.
• UPGRADE-A: Phase 1 trial of UpRi with carboplatin in high-grade serous ovarian cancer (Abstract Number: TPS5613), presented by John Hays, MD on June 5.

These presentations highlight Mersana's ongoing commitment to developing innovative cancer therapies.

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the acceptance of multiple abstracts for poster presentations at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place in Chicago from June 2-6, 2023.

Presentation details are as follows:

• XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers
  Abstract Number: TPS3154
  Presenter: Erika Hamilton, MD, Director, Breast Cancer Research Program, Sarah Cannon Research Institute at Tennessee Oncology
  Session Track & Title: Poster Session – Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
  Session Date & Time: June 3 from 8:00-11:00 a.m. CT
• Correlating expression of NaPi2b and FRa in high grade serous ovarian cancer (HGSOC)
  Abstract Number: 5545
  Presenter: Debra Richardson, MD, Associate Professor, Obstetrics & Gynecology and Section Chief of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center
  Session Track & Title: Poster Session - Gynecologic Cancer
  Session Date & Time: June 5 from 1:15-4:15 p.m. CT
• UP-NEXT (GOG-3049/ENGOT-Ov71-NSGO-CTU): A study of upifitamab rilsodotin (UpRi), a NaPi2b-directed antibody drug conjugate (ADC), in platinum-sensitive recurrent ovarian cancer
  Abstract Number: TPS5614
  Presenter: Debra Richardson, MD, Associate Professor, Obstetrics & Gynecology and Section Chief of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Sciences Center
  Session Track & Title: Poster Session – Gynecologic Cancer
  Session Date & Time: June 5 from 1:15-4:15 p.m. CT
• UPGRADE-A: Phase 1 expansion trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi) in combination with carboplatin in patients with high-grade serous ovarian cancer (HGSOC)
  Abstract Number: TPS5613
  Presenter: John Hays, MD, PhD, Assistant Professor, Department of Internal Medicine, Division of Medical Oncology, The Ohio State University
  Session Track & Title: Poster Session – Gynecologic Cancer
  Session Date & Time: June 5 from 1:15-4:15 p.m. CT

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer; UPGRADE-A, a Phase 1 clinical trial evaluating UpRi in combination with carboplatin; and UP-NEXT, a Phase 3 clinical trial of UpRi as monotherapy maintenance following treatment with platinum doublets in recurrent platinum-sensitive ovarian cancer. Mersana's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase 1 clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets. In addition, multiple partners are using Mersana’s platforms to advance their ADC pipelines. Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.

Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com

FAQ

What abstracts did Mersana Therapeutics present at the 2023 ASCO Meeting?

Mersana Therapeutics presented multiple abstracts on their antibody-drug conjugates at the 2023 ASCO Annual Meeting.

When is the 2023 ASCO Annual Meeting?

The 2023 ASCO Annual Meeting is taking place from June 2-6, 2023, in Chicago.

What is the focus of Mersana Therapeutics' research?

Mersana Therapeutics focuses on developing antibody-drug conjugates targeting cancers with high unmet medical needs.

Who presented the abstract for XMT-1660 at ASCO 2023?

The abstract for XMT-1660 was presented by Erika Hamilton, MD.

What is the significance of the UP-NEXT study by Mersana?

The UP-NEXT study evaluates upifitamab rilsodotin in patients with platinum-sensitive recurrent ovarian cancer.